Publicacions - IR Sant Pau

Cercar

01/01/2022 Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study

Trickey A., Zhang L., Gill M.J., Bonnet F., Burkholder G., Castagna A., Cavassini M., Cichon P., Crane H., Domingo P., Grabar S., Guest J., Obel N., Psichogiou M., Rava M., Reiss P., Rentsch C.T., Riera M., Schuettfort G., Silverberg M.J., Smith C., Stecher M., Sterling T.R., Ingle S.M., Sabin C.A., Sterne J.A.C.. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022; 9(6)DOI:10.1016/S2352-3018(22)00046-7. PMID:35659335. IF:(Q/D).

01/01/2022 Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update)

Riancho J.A., Peris P., González-Macías J., Pérez-Castrillón J.L., Cannata Andía J., Cano A., Carbonell Abella C., Casado Burgos E., Ciria Recasens M., Corral-Gudino L., del Pino Montes J., Del Río Barquero L.M., Díaz Curiel M., Díez Pérez A., García Vadillo A., Gómez Alonso C., Gómez de Tejada Romero M.J., Guañabens N., Hawkins Carranza F., Jódar Gimeno E., Malouf Sierra J., Martínez Díaz-Guerra G., Monegal Brancos A., Muñoz Torres M., Naves Díaz M., Nogues X., Nolla J.M., Olmos Martínez J.M., Peris Bernal P., Quesada Gómez J.M., Rodríguez García M., Sosa Henríquez M., Torrijos Eslava A., Valero Díaz de Lamadrid C.. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Revista De Osteoporosis Y Metabolismo Mineral. 2022; 14(1)DOI:10.4321/S1889-836X2022000100002. PMID:. IF:(Q/D).

14/10/2025 Ending diagnostic odyssey by reanalysis of whole exome sequencing data: reclassification of suspected Fanconi anemia cases to dyskeratosis congenita and Diamond-Blackfan anemia

Tejero, E, de Haro, MJR, Pujol, R, Bogliolo, M, Rodríguez-Santiago, B, Surrallés, J. Ending diagnostic odyssey by reanalysis of whole exome sequencing data: reclassification of suspected Fanconi anemia cases to dyskeratosis congenita and Diamond-Blackfan anemia. Orphanet Journal of Rare Diseases. 2025; 20(1)DOI:10.1186/s13023-025-03928-5. PMID:41088272. IF:3.500(Q2/4D).

01/10/2025 Eltrombopag for Bone Marrow Failure in Fanconi Anemia: Results From the Phase II Clinical Trial FANCREV

Iriondo, J, Zubicaray, J, Rio, P, Catala, A, Solsona, M, Sanz, A, Gomez, A, Sebastian, E, de la Cruz, A, Galan, A, Navarro, S, Larcher, L, de Andoin, NG, Uriz, JJ, Vagace, JM, de Pablo, JG, Pujol, MR, Nicoletti, E, Surralles, J, Martin-Prado, S, Schwartz, JD, Soulier, J, Bueren, JA, Sevilla, J. Eltrombopag for Bone Marrow Failure in Fanconi Anemia: Results From the Phase II Clinical Trial FANCREV. EUROPEAN JOURNAL OF HAEMATOLOGY. 2025; 115(4)DOI:10.1111/ejh.70007. PMID:40665878. IF:2.300(Q2/5D).

01/05/2025 Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients

Beddok, A, Velleuer, E, Fontbrune, FSD, Brakenhoff, RH, Dalle, JH, Dufour, C, Faivre, S, Genet, C, Klijanienko, J, Krieg, C, Leblanc, T, Martinez, P, Latour, RP, Rigolet, A, Saintigny, P, Lyonnet, DS, Soulier, J, Surralles, J, Schramm, M, Thariat, J. Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients. CANCER LETTERS. 2025; 617DOI:10.1016/j.canlet.2025.217529. PMID:40054658. IF:10.100(Q1/1D).

01/02/2025 Prognostic significance of mutation type and chromosome fragility in Fanconi anemia

Ramírez, MJ, Pujol, R, Minguillón, J, Bogliolo, M, Persico, I, Cavero, D, de la Cal, A, Río, P, Navarro, S, Casado, JA, Bailador, A, de la Fuente, AS, de Heredia, ML, Almazán, F, Antelo, ML, Argilés, B, Badell, I, Baragaño, M, Beléndez, C, Bermúdez, M, Bernués, M, Buedo, MI, Carrasco, E, Català, A, Costa, D, Cuesta, I, Fernández-Delgado, R, Fernández-Teijeir, A, Figuera, A, García, M, Gondra, A, González, M, Muñiz, SG, Hernández-Rodríguez, I, Ibañez, F, Kelleher, NJ, Lendínez, F, López, M, López-Almaraz, R, Marchante, I, Mendoza, C, Nieto, J, Ojeda, E, Payán-Pernía, S, Peláez, I, de Soto, IP, Portugal, R, Ramos-Arroyo, MA, Regueiro, A, Rodríguez, A, Rosell, J, Saez, R, Sánchez, J, Sánchez, M, Senent, ML, Tapia, M, Trujillo-Quintero, JP, Vagace, JM, Verdú-Amorós, J, Verdugo, V, Vidales, I, Villarreal, J, Díaz-de-Heredia, C, Sevilla, J, Bueren, J, Surralles, J. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. AMERICAN JOURNAL OF HEMATOLOGY. 2025; 100(2)DOI:10.1002/ajh.27520. PMID:39562502. IF:9.900(Q1/1D).

01/01/2025 Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment

Camps-Fajol, C, Cavero, D, Minguillon, J, Surralles, J. Targeting protein-protein interactions in drug discovery: Modulators approved or in clinical trials for cancer treatment. PHARMACOLOGICAL RESEARCH. 2025; 211DOI:10.1016/j.phrs.2024.107544. PMID:39667542. IF:10.500(Q1/1D).

01/01/2025 A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps

Segarra-Casas, A, Iruzubieta, P, Kapetanovic, S, Hernández-Laín, A, Jericó, I, Fernández-Torrón, R, Maneiro, M, Marco-Moreno, P, Zelaya-Huerta, MV, Rodríguez-Santiago, B, Calafell, F, Töpf, A, Straub, V, Vallejo-Illarramendi, A, de Munain, AL, Gallano, P, Gonzalez-Quereda, L. A founder variant in the RYR1 gene is associated with hyperCKemia, myalgia and muscle cramps. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(1)DOI:10.1111/ene.16471. PMID:39742415. IF:3.900(Q1/3D).

21/12/2024 Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials

Río, P, Zubicaray, J, Navarro, S, Gálvez, E, Sánchez-Domínguez, R, Nicoletti, E, Sebastian, E, Rothe, M, Pujol, R, Bogliolo, M, John-Neek, P, Bastone, AL, Schambach, A, Wang, W, Schmidt, M, Larcher, L, Segovia, JC, Yáñez, RM, Alberquilla, O, Diez, B, Fernández-García, M, García-García, L, Ramírez, M, Galy, A, Lefrere, F, Cavazzana, M, Leblanc, T, de Andoin, NG, López-Almaraz, R, Catala, A, Barquinero, J, Rodríguez-Perales, S, Rao, G, Surrallés, J, Soulier, J, Díaz-de-Heredia, C, Schwartz, JD, Sevilla, J, Bueren, JA. Haematopoietic gene therapy of non-conditioned patients with Fanconi anaemia-A: results from open-label phase 1/2 (FANCOLEN-1) and long-term clinical trials. LANCET. 2024; 404(10471)DOI:10.1016/S0140-6736(24)01880-4. PMID:39642902. IF:88.500(Q1/1D).

20/07/2023 A self-repair history: compensatory effect of a de novo variant on the FANCA c.2778+83C & gt;G splicing mutation

Persico I., Fontana G., Faleschini M., Zanchetta M.E., Ammeti D., Cappelli E., Corsolini F., Mosa C., Guarina A., Bogliolo M., Surrallés J., Dufour C., Farruggia P., Savoia A., Bottega R.. A self-repair history: compensatory effect of a de novo variant on the FANCA c.2778+83C & gt;G splicing mutation. Frontiers in Genetics. 2023; 14DOI:10.3389/fgene.2023.1209138. PMID:37547463. IF:2.800(Q2/5D).

21/06/2023 Genotype and clinical characteristics of patients with Wolfram syndrome and WFS1-related disorders

Lee, EM, Verma, M, Palaniappan, N, Pope, EM, Lee, S, Blacher, L, Neerumalla, P, An, W, Campbell, T, Brown, C, Hurst, S, Marshall, B, Hershey, T, Nunes, V, de Heredia, ML, Urano, F. Genotype and clinical characteristics of patients with Wolfram syndrome and WFS1-related disorders. Frontiers in Genetics. 2023; 14DOI:10.3389/fgene.2023.1198171. PMID:37415600. IF:2.800(Q2/5D).

01/04/2023 Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry

Dobarro, D, Donoso-Trenado, V, Sole-Gonzalez, E, Moliner-Abos, C, Garcia-Pinilla, JM, Lopez-Fernandez, S, Ruiz-Bustillo, S, Diez-Lopez, C, Castrodeza, J, Mendez-Fernandez, AB, Vaqueriza-Cubillo, D, Cobo-Marcos, M, Tobar, J, Sagasti-Aboitiz, I, Rodriguez, M, Escolar, V, Abecia, A, Codina, P, Gomez-Otero, I, Pastor, F, Marzoa-Rivas, R, Gonzalez-Babarro, E, de Juan-Baguda, J, Melendo-Viu, M, de Frutos, F, Gonzalez-Costello, J. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. ESC Heart Failure. 2023; 10(2)DOI:10.1002/ehf2.14278. PMID:36655614. IF:3.200(Q2/3D).

01/01/2023 A crowdsourcing database for the copy-number variation of the Spanish population

López-López D., Roldán G., Fernández-Rueda J.L., Bostelmann G., Carmona R., Aquino V., Perez-Florido J., Ortuño F., Pita G., Núñez-Torres R., González-Neira A., Alonso A., Salgado-Garrido J., Pasalodos-Sanchez S., Ayuso C., Minguez P., Avila-Fernandez A., Corton M., Artuch R., Borrego S., Antiñolo G., Carracedo A., Amigo J., Castaño L.A., Tejada I., Delmiro A., Espinos C., Grinberg D., Guillén E., Lapunzina P., Lopez-Escámez J.A., Gallego-Martinez A., Martí R., Rovira E., Millán J.M., Moreno M.A., Morin M., Moreno-Galdó A., Fernández-Cancio M., Morte B., Mulero V., García D., Nunes V., Palau F., Perez B., Jurado L.P., Perona R., Pujol A., Ramos F., Lopez E., Ribes A., Rosell J., Surrallés J., Peña-Chilet M., Dopazo J.. A crowdsourcing database for the copy-number variation of the Spanish population. Human Genomics. 2023; 17(1)DOI:10.1186/s40246-023-00466-8. PMID:36894999. IF:3.800(Q2/3D).

01/01/2023 Repetitive ambulatory levosimendan as a bridge to heart transplantation

de Juan Bagudá J., de Frutos F., López-Vilella R., Couto Mallón D., Guzman-Bofarull J., Blazquez-Bermejo Z., Cobo-Belaustegui M., Mitroi C., Pastor-Pérez F.J., Moliner-Abós C., Rangel-Sousa D., Díaz-Molina B., Tobar-Ruiz J., Salterain Gonzalez N., García-Pinilla J.M., García-Cosío Carmena M.D., Crespo-Leiro M.G., Dobarro D., Almenar L., Delgado-Jiménez J.F., Paredes-Galán E., González-Vílchez F., González-Costello J.. Repetitive ambulatory levosimendan as a bridge to heart transplantation. REVISTA ESPANOLA DE CARDIOLOGIA. 2023; DOI:10.1016/j.recesp.2023.07.005. PMID:. IF:(Q/D).

01/08/2022 Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia

Casado, JA, Valeri, A, Sanchez-Dominguez, R, Vela, P, Lopez, A, Navarro, S, Alberquilla, O, Hanenberg, H, Pujol, R, Segovia, JC, Minguillon, J, Surralles, J, de Heredia, CD, Sevilla, J, Rio, P, Bueren, JA. Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia. JOURNAL OF CLINICAL INVESTIGATION. 2022; 132(15)DOI:10.1172/JCI142842. PMID:35671096. IF:15.900(Q1/1D).

28/06/2022 Metformin for treatment of cytopenias in children and young adults with Fanconi anemia

Pollard, JA, Furutani, E, Liu, SS, Esrick, E, Cohen, LE, Bledsoe, J, Liu, CW, Lu, K, de Haro, MJR, Sumalles, J, Malsch, M, Kuniholm, A, Galvin, A, Armant, M, Kim, AS, Ballotti, K, Moreau, L, Zhou, Y, Babushok, D, Boulad, F, Carroll, C, Hartung, H, Hont, A, Nakano, T, Olson, T, Sze, SG, Thompson, AA, Wlodarski, MW, Gu, XS, Libermann, TA, D'Andrea, A, Grompe, M, Weller, E, Shimamura, A. Metformin for treatment of cytopenias in children and young adults with Fanconi anemia. Blood Advances. 2022; 6(12)DOI:10.1182/bloodadvances.2021006490. PMID:35500223. IF:7.500(Q1/2D).

01/05/2022 CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative

Luque, J, Mendes, I, Gomez, B, Morte, B, de Heredia, ML, Herreras, E, Corrochano, V, Bueren, J, Gallano, P, Artuch, R, Fillat, C, Perez-Jurado, LA, Montoliu, L, Carracedo, A, Millan, JM, Webb, SM, Palau, F, Lapunzina, P. CIBERER: Spanish national network for research on rare diseases: A highly productive collaborative initiative. CLINICAL GENETICS. 2022; 101(5-6)DOI:10.1111/cge.14113. PMID:35060122. IF:3.500(Q2/4D).

01/01/2022 Fanconi-like anemia related to a FANCM mutation

Encarnacion, JA, Cerezuela, P, Espanol, I, Garcia, MR, Manso, C, De la Fuente, I, Garrigos, N, Viney, A, Minguillon, J, Surralles, J. Fanconi-like anemia related to a FANCM mutation. European Journal of Medical Genetics. 2022; 65(1)DOI:10.1016/j.ejmg.2021.104399. PMID:34793962. IF:1.900(Q4/8D).

01/01/2022 CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

Minguillon, J, Ramirez, MJ, Rovirosa, L, Bustamante-Madrid, P, Camps-Fajol, C, de Garibay, GR, Shimelis, H, Montanuy, H, Pujol, R, Hernandez, G, Bogliolo, M, Castillo, P, Soucy, P, Martrat, G, Gomez, A, Cuadras, D, Garcia, MJ, Gayarre, J, Lazaro, C, Benitez, J, Couch, FJ, Pujana, MA, Surralles, J. CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival. Cancers. 2022; 14(2)DOI:10.3390/cancers14020353. PMID:35053516. IF:5.200(Q2/3D).

01/01/2022 Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer

Webster A.L.H., Sanders M.A., Patel K., Dietrich R., Noonan R.J., Lach F.P., White R.R., Goldfarb A., Hadi K., Edwards M.M., Donovan F.X., Hoogenboezem R.M., Jung M., Sridhar S., Wiley T.F., Fedrigo O., Tian H., Rosiene J., Heineman T., Kennedy J.A., Bean L., Rosti R.O., Tryon R., Gonzalez A.-M., Rosenberg A., Luo J.-D., Carroll T.S., Shroff S., Beaumont M., Velleuer E., Rastatter J.C., Wells S.I., Surrallés J., Bagby G., MacMillan M.L., Wagner J.E., Cancio M., Boulad F., Scognamiglio T., Vaughan R., Beaumont K.G., Koren A., Imielinski M., Chandrasekharappa S.C., Auerbach A.D., Singh B., Kutler D.I., Campbell P.J., Smogorzewska A.. Genomic signature of Fanconi anaemia DNA repair pathway deficiency in cancer. NATURE. 2022; 612(7940)DOI:10.1038/s41586-022-05253-4. PMID:36450981. IF:64.800(Q1/1D).

01/01/2022 Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia

Errazquin R., Page A., Suñol A., Segrelles C., Carrasco E., Peral J., Garrido-Aranda A., Del Marro S., Ortiz J., Lorz C., Minguillon J., Surralles J., Belendez C., Alvarez M., Balmaña J., Bravo A., Ramirez A., Garcia-Escudero R.. Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia. ORAL ONCOLOGY. 2022; 134DOI:10.1016/j.oraloncology.2022.106184. PMID:36191479. IF:4.800(Q1/1D).

10/09/2021 Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes

Sevilla, J, Navarro, S, Rio, P, Sanchez-Dominguez, R, Zubicaray, J, Galvez, E, Merino, E, Sebastian, E, Azqueta, C, Casado, JA, Segovia, JC, Alberquilla, O, Bogliolo, M, Roman-Rodriguez, FJ, Gimenez, Y, Larcher, L, Salgado, R, Pujol, RM, Hladun, R, Castillo, A, Soulier, J, Querol, S, Fernandez, J, Schwartz, J, de Andoin, NG, Lopez, R, Catala, A, Surralles, J, Diaz-de-Heredia, C, Bueren, JA. Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy-Methods & Clinical Development. 2021; 22DOI:10.1016/j.omtm.2021.06.001. PMID:34485595. IF:5.849(Q2/4D).

09/09/2021 Clinical consequences of BRCA2 hypomorphism

Castells-Roca, L, Gutierrez-Enriquez, S, Bonache, S, Bogliolo, M, Carrasco, E, Aza-Carmona, M, Montalban, G, Munoz-Subirana, N, Pujol, R, Cruz, C, Llop-Guevara, A, Ramirez, MJ, Saura, C, Lasa, A, Serra, V, Diez, O, Balmana, J, Surralles, J. Clinical consequences of BRCA2 hypomorphism. npj Breast Cancer. 2021; 7(1)DOI:10.1038/s41523-021-00322-9. PMID:34504103. IF:7.519(Q1/3D).

01/07/2021 Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus

Isla, D, de Castro, J, Garcia-Campelo, R, Majem, M, Vicente, D, Juan-Vidal, O. Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus. Clinical & Translational Oncology. 2021; 23(7)DOI:10.1007/s12094-020-02518-0. PMID:33210237. IF:3.340(Q3/7D).

01/03/2022 Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Garcia-Alfonso, P, Saiz-Rodriguez, M, Mondejar, R, Salazar, J, Paez, D, Borobia, AM, Safont, MJ, Garcia-Garcia, I, Colomer, R, Garcia-Gonzalez, X, Herrero, MJ, Lopez-Fernandez, LA, Abad-Santos, F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clinical & Translational Oncology. 2022; 24(3)DOI:10.1007/s12094-021-02708-4. PMID:34773566. IF:3.400(Q3/6D).

15/01/2022 Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study

Hentrich, MU, Bower, M, Daugaard, G, Dieing, A, Bickel, M, Berretta, M, Lesmeister, F, Jurinovic, V, Stoehr, A, Heinzelbecker, J, Krznaric, I, Dieckmann, KP, Necchi, A, Rey, PM, Rockstroh, JK, Brito, M, Pfister, D, Hoffmann, C. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. CANCER. 2022; 128(2)DOI:10.1002/cncr.33928. PMID:34592009. IF:6.200(Q1/3D).

01/01/2022 SELNET clinical practice guidelines for soft tissue sarcoma and GIST

Blay, JY, Hindi, N, Bollard, J, Aguiar, S, Angel, M, Araya, B, Badilla, R, Bernabeu, D, Campos, F, Caro-Sanchez, CHS, Carvajal, B, Montoya, AC, Casavilca-Zambrano, S, Castro-Oliden, V, Chacon, M, Clara, M, Collini, P, Genoroso, RC, Costa, FD, Cuellar, M, dei Tos, AP, Malagon, HRD, Donati, D, Dufresne, A, Eriksson, M, Farias-Loza, M, Fernandez, P, Frezza, AM, Frisoni, T, Garcia-Ortega, DY, Gelderblom, H, Gouin, F, Gomez-Mateo, MC, Gronchi, A, Haro, J, Huanca, L, Jimenez, N, Karanian, M, Kasper, B, David, BBL, Lopez-Pousa, A, Lutter, G, Martinez-Said, H, Martinez-Tlahuel, J, Mello, CA, Perez, JMM, David, SM, Nascimento, AG, Ortiz-Cruz, EJ, Palmerini, E, Patel, S, Pfluger, Y, Provenzano, S, Righi, A, Rodriguez, A, Salas, R, Santos, TTG, Scotlandi, K, Soule, T, Stacchiotti, S, Valverde, C, Waisberg, F, Estrada, EZ, Martin-Broto, J. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS. 2022; 102DOI:10.1016/j.ctrv.2021.102312. PMID:34798363. IF:11.800(Q1/1D).

01/01/2022 Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study

Provencio, M, Rodriguez-Abreu, D, Ortega, AL, Serrano, G, Aguado, C, Franco, F, Gutierrez, V, Vivanco, GL, Guirado, M, Benitez, G, Estival, A, Calvo, V, Jimenez, B, Arasanz, H, Coves, J, Majem, M, Massuti, B, Vazquez, S, Juan-Vidal, O, Collazo-Lorduy, A, Gozalvez, CL, Del Barco, E, Rosero, A, Bosch-Barrerra, J, Moreno, MA, Mielgo-Rubio, X, Villa, JC, Lopez-Martin, A, Cordoba, JF, Aparisi, FD, Zafra, M, Mosquera, J, Altozano, JP, Nadal, E, Catot, S, Balsalobre, J, De Portugal, T, Martin, P, De Juan, SC, Cobo, M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Translational Lung Cancer Research. 2022; 11(1)DOI:10.21037/tlcr-21-504. PMID:35242627. IF:4.000(Q2/4D).

01/12/2021 First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

Majem, M, Sullivan, I, Viteri, S, Lopez-Vivanco, G, Cobo, M, Sanchez, JM, Garcia-Gonzalez, J, Garde, J, Sampayo, M, Martrat, G, Malfettone, A, Karachaliou, N, Molina-Vila, MA, Rosell, R. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. EUROPEAN JOURNAL OF CANCER. 2021; 159DOI:10.1016/j.ejca.2021.09.039. PMID:34763195. IF:10.002(Q1/2D).

01/11/2021 Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy

Cortellini, A, Ricciuti, B, Facchinetti, F, Alessi, JVM, Venkatraman, D, Dall'Olio, FG, Cravero, P, Vaz, VR, Ottaviani, D, Majem, M, Piedra, A, Sullivan, I, Lee, KA, Lamberti, G, Hussain, N, Clark, J, Bolina, A, Barba, A, Benitez, JC, Gorria, T, Mezquita, L, Hoton, D, Nana, FA, Besse, B, Awad, MM, Pinato, DJ. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.08.1744. PMID:34400292. IF:51.769(Q1/1D).

01/11/2021 Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis

Rofes, P, Gonzalez, S, Navarro, M, Moreno-Cabrera, JM, Solanes, A, Darder, E, Carrasco, E, Iglesias, S, Salinas, M, Gomez, C, Velasco, A, Tuset, N, Varela, M, Llort, G, Cajal, TRY, Grau, E, Duenas, N, Merlano, ND, Matias-Guiu, X, Rivera, B, Balmana, J, Pineda, M, Brunet, J, Capella, G, del Valle, J, Lazaro, C. Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancer-Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. JOURNAL OF MOLECULAR DIAGNOSTICS. 2021; 23(11)DOI:10.1016/j.jmoldx.2021.07.024. PMID:34454113. IF:5.341(Q1/3D).

01/11/2021 Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Gronchi, A, Miah, AB, DeiTos, AP, Abecassis, N, Bajpai, J, Bauer, S, Biagini, R, Bielack, S, Blay, JY, Bolle, S, Bonvalot, S, Boukovinas, I, Bovee, JVMG, Boye, K, Brennan, B, Brodowicz, T, Buonadonna, A, DeAlava, E, Del Muro, XG, Dufresne, A, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Frezza, AM, Gasperoni, S, Gelderblom, H, Gouin, F, Grignani, G, Haas, R, Hassan, AB, Hecker-Nolting, S, Hindi, N, Hohenberger, P, Joensuu, H, Jones, RL, Jungels, C, Jutte, P, Kager, L, Kasper, B, Kawai, A, Kopeckova, K, Krakorova, DA, Le Cesne, A, LeGrange, F, Legius, E, Leithner, A, Lopez-Pousa, A, Martin-Broto, J, Merimsky, O, Messiou, C, Mir, O, Montemurro, M, Morland, B, Morosi, C, Palmerini, E, Pantaleo, MA, Piana, R, Piperno-Neumann, S, Reichardt, P, Rutkowski, P, Safwat, AA, Sangalli, C, Sbaraglia, M, Scheipl, S, Schoffski, P, Sleijfer, S, Strauss, D, Strauss, S, SundbyHall, K, Trama, A, Unk, M, VandeSande, MAJ, VanderGraaf, WTA, van Houdt, WJ, Frebourg, T, Casali, PG, Stacchiotti, S, ESMO Guidelines Comm, EURACAN, GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANNALS OF ONCOLOGY. 2021; 32(11)DOI:10.1016/j.annonc.2021.07.006. PMID:34303806. IF:51.769(Q1/1D).

01/11/2021 The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis

Dabush, DR, Shepshelovich, D, Shochat, T, Tibau, A, Amir, E, Goldvaser, H. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis. CANCER TREATMENT REVIEWS. 2021; 100DOI:10.1016/j.ctrv.2021.102293. PMID:34543860. IF:13.608(Q1/1D).

01/11/2021 Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Casarrubios, M, Cruz-Bermudez, A, Nadal, E, Insa, A, Campelo, MDG, Lazaro, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, de Castro-Carpeno, J, Cobo, M, Lopez-Vivanco, G, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Barquin, M, Laza-Briviesca, R, Sierra-Rodero, B, Parra, ER, Sanchez-Espiridion, B, Rocha, P, Kadara, H, Wistuba, II, Romero, A, Calvo, V, Provencio, M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. CLINICAL CANCER RESEARCH. 2021; 27(21)DOI:10.1158/1078-0432.CCR-21-1200. PMID:34376534. IF:13.801(Q1/1D).

01/11/2021 A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer

Wu, YL, Tsuboi, M, John, T, Grohe, C, Majem, M, Goldman, JW, Laktionov, K, Kim, SW, Kato, T, Vu, HV, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Hodge, R, Atasoy, A, Rukazenkov, Y, Herbst, RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology. 2021; 17(35)DOI:10.2217/fon-2021-0752. PMID:34723634. IF:3.674(Q3/7D).

01/11/2021 A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study

Bancroft, EK, Page, EC, Brook, MN, Thomas, S, Taylor, N, Pope, J, McHugh, J, Jones, AB, Karlsson, Q, Merson, S, Ong, KR, Hoffman, J, Huber, C, Maehle, L, Grindedal, EM, Stormorken, A, Evans, DG, Rothwell, J, Lalloo, F, Brady, AF, Bartlett, M, Snape, K, Hanson, H, James, P, McKinley, J, Mascarenhas, L, Syngal, S, Ukaegbu, C, Side, L, Thomas, T, Barwell, J, Teixeira, MR, Izatt, L, Suri, M, Macrae, FA, Poplawski, N, Chen-Shtoyerman, R, Ahmed, M, Musgrave, H, Nicolai, N, Greenhalgh, L, Brewer, C, Pachter, N, Spigelman, AD, Azzabi, A, Helfand, BT, Halliday, D, Buys, S, Cajal, TRY, Donaldson, A, Cooney, KA, Harris, M, McGrath, J, Davidson, R, Taylor, A, Cooke, P, Myhill, K, Hogben, M, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Dias, A, Dudderidge, T, Eccles, DM, Green, K, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lilja, H, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, AV, Moynihan, C, Raghallaigh, HN, Rennert, G, Collier, R, Offman, J, Kote-Jarai, Z, Eeles, RA. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. LANCET ONCOLOGY. 2021; 22(11)DOI:10.1016/S1470-2045(21)00522-2. PMID:34678156. IF:54.433(Q1/1D).

03/10/2021 Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients

Riera, P, Paez, D. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients. Expert Opinion on Drug Metabolism & Toxicology. 2021; 17(10)DOI:10.1080/17425255.2021.1974397. PMID:34486919. IF:4.936(Q1/3D).

01/10/2021 Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC

Herbst, RS, Garon, EB, Kim, DW, Cho, BC, Gervais, R, Perez-Gracia, JL, Han, JY, Majem, M, Forster, MD, Monnet, I, Novello, S, Gubens, MA, Boyer, M, Su, WC, Samkari, A, Jensen, EH, Kobie, J, Piperdi, B, Baas, P. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Research in Social & Administrative Pharmacy. 2021; 16(10)DOI:10.1016/j.jtho.2021.05.001. PMID:34048946. IF:3.348(Q2/5D).

01/10/2021 Electronic health records and patient registries in medical oncology departments in Spain

Ribelles, N, Alvarez-Lopez, I, Arcusa, A, Chacon, JI, de la Haba, J, Garcia-Corbacho, J, Garcia-Mata, J, Jara, C, Jerez, JM, Lazaro-Quintela, M, Leon-Mateos, L, Ramirez-Merino, N, Tibau, A, Garcia-Palomo, A. Electronic health records and patient registries in medical oncology departments in Spain. Clinical & Translational Oncology. 2021; 23(10)DOI:10.1007/s12094-021-02614-9. PMID:33864619. IF:3.340(Q3/7D).

01/10/2021 Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations

Riudavets, M, Sullivan, I, Abdayem, P, Planchard, D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021; 6(5)DOI:10.1016/j.esmoop.2021.100260. PMID:34479034. IF:6.883(Q1/3D).

01/09/2021 Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Blackhall, F, Jao, K, Greillier, L, Cho, BC, Penkov, K, Reguart, N, Majem, M, Nackaerts, K, Syrigos, K, Hansen, K, Schuette, W, Cetnar, J, Cappuzzo, F, Okamoto, I, Erman, M, Langer, SW, Kato, T, Groen, H, Sun, ZW, Luo, Y, Tanwani, P, Caffrey, L, Komarnitsky, P, Reinmuth, N. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology. 2021; 16(9)DOI:10.1016/j.jtho.2021.02.009. PMID:33607312. IF:20.121(Q1/1D).

01/09/2021 LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Garrido, P, Paz-Ares, L, Majem, M, Moran, T, Trigo, JM, Bosch-Barrera, J, Garcia-Campelo, R, Gonzalez-Larriba, JL, Sanchez-Torres, JM, Isla, D, Vinolas, N, Camps, C, Insa, A, Juan, O, Massuti, B, Paredes, A, Artal, A, Lopez-Brea, M, Palacios, J, Felip, E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 2021; 10(17)DOI:10.1002/cam4.4135. PMID:34296539. IF:4.711(Q2/5D).

01/09/2021 Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

Vokinger, KN, Hwang, TJ, Daniore, P, Lee, CC, Tibau, A, Grischott, T, Rosemann, TJ, Kesselheim, AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology. 2021; 7(9)DOI:10.1001/jamaoncol.2021.2026. PMID:34196656. IF:33.012(Q1/1D).

01/09/2021 Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors

Moreno, V, Greil, R, Yachnin, J, Majem, M, Wermke, M, Arkenau, HT, Basque, JR, Nidamarthy, PK, Kapoor, S, Cui, XM, Giovannini, M. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. CLINICAL THERAPEUTICS. 2021; 43(6)DOI:10.1016/j.clinthera.2021.04.006. PMID:34053700. IF:3.637(Q2/5D).

01/08/2021 Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)

Jimenez-Labaig, P, Pacheco-Barcia, V, Cebria, A, Galvez, F, Obispo, B, Paez, D, Quilez, A, Quintanar, T, Ramchandani, A, Remon, J, Rogado, J, Sanchez, DA, Sanchez-Canovas, M, Sanz-Garcia, E, Sesma, A, Tarazona, N, Cotes, A, Gonzalez, E, Bosch-Barrera, J, Fernandez, A, Felip, E, Vera, R, Rodriguez-Lescure, A, Elez, E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021; 6(4)DOI:10.1016/j.esmoop.2021.100215. PMID:34325108. IF:6.883(Q1/3D).

01/08/2021 Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations

Wilson, BE, Desnoyers, A, Nadler, MB, Tibau, A, Amir, E. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations. Cancer Medicine. 2021; 10(16)DOI:10.1002/cam4.4029. PMID:34323019. IF:4.711(Q2/5D).

09/07/2021 Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study

Gil-Gil, MJ, Bellet, M, Bergamino, M, Morales, S, Barnadas, A, Manso, L, Saura, C, Fernandez-Ortega, A, Garcia-Martinez, E, Martinez-Janez, N, Mele, M, Villagrasa, P, Celiz, P, Martin, XP, Ciruelos, E, Pernas, S. Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Frontiers in Oncology. 2021; 11DOI:10.3389/fonc.2021.645026. PMID:34307126. IF:5.738(Q2/4D).

01/07/2021 Lung cancer patients with COVID-19 in Spain: GRAVID study

Provencio, M, Gallego, JMM, Calles, A, Antonanzas, M, Pangua, C, Rubio, XM, Nadal, E, Castro, RL, Lopez-Martin, A, Del Barco, E, Domine, M, Franco, F, Diz, P, Sandoval, C, Girona, ES, Sullivan, I, Sala, MA, Ledo, GG, Cucurull, M, Mosquera, J, Martinez, M, Chara, LE, Arriola, E, Herrera, BE, Jarabo, JR, Alvarez, RA, Baena, J, Cao, MG. Lung cancer patients with COVID-19 in Spain: GRAVID study. LUNG CANCER. 2021; 157DOI:10.1016/j.lungcan.2021.05.014. PMID:34016490. IF:6.081(Q1/3D).

01/07/2021 Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics

Mezquita, L, Preeshagul, I, Auclin, E, Saravia, D, Hendriks, L, Rizvi, H, Park, W, Nadal, E, Martin-Romano, P, Ruffinelli, JC, Ponce, S, Audigier-Valette, C, Carnio, S, Blanc-Durand, F, Bironzo, P, Tabbo, F, Reale, ML, Novello, S, Hellmann, MD, Sawan, P, Girshman, J, Plodkowski, AJ, Zalcman, G, Majem, M, Charrier, M, Naigeon, M, Rossoni, C, Mariniello, A, Paz-Ares, L, Dingemans, AM, Planchard, D, Cozic, N, Cassard, L, Lopes, G, Chaput, N, Arbour, K, Besse, B. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. EUROPEAN JOURNAL OF CANCER. 2021; 151DOI:10.1016/j.ejca.2021.03.011. PMID:34022698. IF:10.002(Q1/2D).

01/07/2021 Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

Alvarez-Mancenido, F, Jimenez-Fonseca, P, Carmona-Bayonas, A, Arrazubi, V, Hernandez, R, Cano, JM, Custodio, A, Pijaume, CP, Aguado, G, Lago, NM, Canovas, MS, Lavin, DC, Visa, L, Martinez-Torron, A, Arias-Martinez, A, Lopez, F, Limon, ML, Tocino, RV, Montes, AF, Alsina, M, Pimentel, P, Reguera, P, Carnicero, AM, Ramchandani, A, Granja, M, Azkarate, A, Richard, MM, Serra, O, Perez, CH, Hurtado, A, Gil-Negrete, A, Sauri, T, del Burgo, PM, Gallego, J. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021; 24(4)DOI:10.1007/s10120-021-01169-6. PMID:33651195. IF:7.701(Q1/2D).

01/07/2021 Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

Laza-Briviesca, R, Cruz-Bermudez, A, Nadal, E, Insa, A, Garcia-Campelo, MD, Huidobro, G, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Caro, RB, Vinolas, N, Aranda, IB, Viteri, S, Massuti, B, Casarrubios, M, Sierra-Rodero, B, Tarin, C, Garcia-Grande, A, Haymaker, C, Wistuba, II, Romero, A, Franco, F, Provencio, M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clinical and Translational Medicine. 2021; 11(7)DOI:10.1002/ctm2.491. PMID:34323406. IF:8.554(Q1/2D).

01/08/2022 The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

Atenza, CZ, Anguera, G, Melia, MR, De Lamo, LA, Sullivan, I, Joaquin, AB, Lopez, JS, Ortiz, MA, Mulet, M, Vidal, S, Majem, M. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. CANCER IMMUNOLOGY IMMUNOTHERAPY. 2022; 71(8)DOI:10.1007/s00262-021-03107-y. PMID:34984538. IF:5.800(Q1/3D).

01/06/2022 Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis

Arriola, E, Gonzalez-Cao, M, Domine, M, De Castro, J, Cobo, M, Bernabe, R, Navarro, A, Sullivan, I, Trigo, JM, Mosquera, J, Crama, L, Isla, D. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncology And Therapy. 2022; 10(1)DOI:10.1007/s40487-021-00182-0. PMID:35032007. IF:(Q/D).

01/04/2022 SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

Remon, J, Bernabe, R, Diz, P, Felip, E, Gonzalez-Larriba, JL, Lazaro, M, Mielgo-Rubio, X, Sanchez, A, Sullivan, I, Massutti, B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02788-w. PMID:35122634. IF:3.400(Q3/6D).

01/04/2022 SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021)

Capdevila, J, Gomez, MA, Guillot, M, Paez, D, Pericay, C, Safont, MJ, Tarazona, N, Vera, R, Vidal, J, Sastre, J. SEOM-GEMCAD-TTD clinical guidelines for localized rectal cancer (2021). Clinical & Translational Oncology. 2022; 24(4)DOI:10.1007/s12094-022-02816-9. PMID:35303269. IF:3.400(Q3/6D).

01/04/2022 Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses

Palassini, E, Mir, O, Grignani, G, Vincenzi, B, Gelderblom, H, Sebio, A, Valverde, C, Baldi, GG, Brunello, A, Cardellino, GG, Marrari, A, Badalamenti, G, Martin-Broto, J, Ferraresi, V, Libertini, M, Turano, S, Gataa, I, Collini, P, Dei Tos, AP, Gennaro, M, Bini, F, Provenzano, S, Lo Vullo, S, Mariani, L, Le Cesne, A, Casali, PG. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analyses. BREAST CANCER RESEARCH AND TREATMENT. 2022; 192(3)DOI:10.1007/s10549-022-06524-4. PMID:35150367. IF:3.800(Q2/5D).

01/03/2022 PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence

Eggermont, AMM, Ascierto, PA, Khushalani, NI, Schadendorf, D, Boland, G, Weber, J, Lewis, KD, Johnson, D, Rivalland, G, Khattak, A, Majem, M, Gogas, H, Long, GV, Currie, SL, Chien, D, Tagliaferri, MA, Carlino, MS, Diab, A. PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology. 2022; 18(8)DOI:10.2217/fon-2021-1286. PMID:35073733. IF:3.300(Q3/6D).

01/03/2022 Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome

Sanchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, Carballal, S, Rodriguez-Alonso, L, Cajal, TRY, Llort, G, Pinol, V, Lopez-Fernandez, A, Salces, I, Pico, MD, Rivas, L, Bujanda, L, Garzon, M, Pizarro, A, de Castro, EM, Lopez-Arias, MJ, Poves, C, Garau, C, Rodriguez-Alcalde, D, Herraiz, M, Alvarez-Urrutia, C, Dacal, A, Carrillo-Palau, M, Cid, L, Ponce, M, Barreiro-Alonso, E, Saperas, E, Aguirre, E, Romero, C, Bastiaansen, B, Gonzalez-Acosta, M, Morales-Romero, B, Ocana, T, Rivero-Sanchez, L, Jung, G, Bessa, X, Cubiella, J, Jover, R, Rodriguez-Moranta, F, Balmana, J, Brunet, J, Castells, A, Dekker, E, Capella, G, Serra-Burriel, M, Moreira, L, Pellise, M, Balaguer, F. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology. 2022; 20(3)DOI:10.1016/j.cgh.2020.11.002. PMID:33157315. IF:12.600(Q1/1D).

01/03/2022 Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Wu, YL, John, T, Grohe, C, Majem, M, Goldman, JW, Kim, SW, Kato, T, Laktionov, K, Vu, HV, Wang, ZJ, Lu, S, Lee, KY, Akewanlop, C, Yu, CJ, de Marinis, F, Bonanno, L, Domine, M, Shepherd, FA, Zeng, LM, Atasoy, A, Herbst, RS, Tsuboi, M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 2022; 17(3)DOI:10.1016/j.jtho.2021.10.014. PMID:34740861. IF:20.400(Q1/1D).

01/02/2022 A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Sooy, RA, Han, JY, Dafni, U, Cho, BC, Yeo, CM, Nadal, E, Carcereny, E, de Castro, J, Sala, MA, Bernabee, R, Coate, L, Pulla, MP, Campelo, RG, Cuffe, S, Hashemi, SMS, Fruh, M, Massuti, B, Garcia-Sanchez, J, Domine, M, Majem, M, Sanchez-Torres, JM, Britschgi, C, Pless, M, Dimopoulou, G, Roschitzki-Voser, H, Ruepp, B, Rosell, R, Stahel, RA, Peters, S. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. ANNALS OF ONCOLOGY. 2022; 33(2)DOI:10.1016/j.annonc.2021.11.010. PMID:34839016. IF:50.500(Q1/1D).